+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Provenge"

Global Cancer Vaccine Market & Clinical Trial Insight 2025 - Product Thumbnail Image

Global Cancer Vaccine Market & Clinical Trial Insight 2025

  • Clinical Trials
  • September 2018
  • 700 Pages
  • Global
From
Loading Indicator

Provenge is a prostate cancer drug developed by Dendreon Corporation. It is a therapeutic vaccine that works by stimulating the body's immune system to recognize and attack prostate cancer cells. Provenge is the first FDA-approved therapeutic cancer vaccine and is used to treat advanced prostate cancer. It is administered as a series of three intravenous infusions over a period of several weeks. Provenge is a relatively new drug and is not widely used. It is typically used in combination with other treatments such as hormone therapy and chemotherapy. It is also used as a last resort for patients who have not responded to other treatments. The Provenge market is highly competitive, with several companies offering similar treatments. Companies such as Merck, Pfizer, and Sanofi are all developing prostate cancer drugs that are similar to Provenge. Other companies such as GlaxoSmithKline, AstraZeneca, and Bristol-Myers Squibb are also researching and developing prostate cancer drugs. Show Less Read more